Tramisol (levamisole) is primarily utilized in veterinary settings for the management of parasitic infections in various livestock, including cattle, sheep, goats, and ostriches.

Quick Facts

• Therapeutic Domain: Veterinary medicine for livestock.
• Primary Use: Supports the treatment of parasitic roundworm (nematode) infestations in animals.
• Condition Management: Provides assistance in clearing specific gastrointestinal and pulmonary parasitic worms.

The medication is indicated to help address infections caused by several important species of roundworms. In cattle, sheep, and goats, this includes support for addressing the presence of common gastrointestinal parasites such as Haemonchus, Trichostrongylus, and Ostertagia species. It also helps in the management of lungworms (Dictyocaulus spp.).

Tramisol works to reduce the parasitic load within the treated animals, which contributes to the overall maintenance of animal health and condition. The agent acts on both the adult and larval forms of susceptible worms.

Levamisole is the active ingredient. This drug is not currently approved for human use in the United States.

Who can and cannot use Tramisol?

Eligibility for Levamisole (Tramisol) is strictly defined by regulatory documents and depends heavily on jurisdiction. The medicine is not approved for any human therapeutic use in the United States, with its authorization restricted to veterinary applications. For international regions where human use (typically as an anthelmintic) is authorized, specific populations are strictly excluded or advised against use.

Absolute Contraindications

The medicine is formally contraindicated and must not be used in the following populations:

• Patients with a known hypersensitivity to levamisole or any of its components.
• Individuals with pre-existing blood disorders, including a history of agranulocytosis or leukopenia.
• Patients with documented severe renal impairment (severe kidney disease).

Population Restrictions

Population Group	Regulatory Status
Adults and Children	Authorized for anthelmintic use in specific international jurisdictions.
Pregnant Women	Not recommended unless absolutely necessary; advised against during the third trimester.
Breastfeeding Mothers	Not recommended; health authorities advise against use.
Hepatic Impairment	Use requires caution in patients with a history of liver diseases.

Interactions with other medicines and products

Tramisol (Levamisole) has officially documented interaction patterns that affect co-administered substances through both pharmacodynamic and pharmacokinetic mechanisms. The regulatory profile establishes specific constraints regarding concurrent substance use.

---

Contraindicated Combinations

• Alcohol (Ethanol): Co-administration is formally prohibited due to a severe pharmacodynamic effect resulting in a disulfiram-like reaction.

Documented Exposure Modification

Interaction documentation indicates that Levamisole can significantly increase the effects of certain medications, which implies an increase in their systemic exposure. This includes:

• Warfarin and Phenytoin, where the co-administration requires careful regulatory consideration to manage the potential for increased activity.

Other Pharmacokinetic Interactions

Co-administration with other anthelmintic agents alters their systemic availability, which is a key consideration in multi-drug regimens. Levamisole has been found to increase the bioavailability of Ivermectin while simultaneously causing a reduction in the bioavailability of Albendazole.

Administration Constraints and Specific Populations

• Administration Timing: For indications related to human use, official prescribing information has mandated taking the medication on an empty stomach.
• Liver Disease: Reduced metabolism and excretion have been observed in models of liver compromise, suggesting a risk of altered clearance and potentially heightened interaction effects in this population.

How Tramisol Works: Mechanism of Action

---

Targets Specific Neuromuscular Signaling

This drug exerts a primary pharmacodynamic effect by acting as an agonist on nicotinic acetylcholine receptors (nAChRs) found in the muscle cells of the targeted organisms. The binding of the drug to these receptors creates a sustained, excessive stimulation, resulting in persistent depolarization of the muscle membrane. This biochemical event initiates a cascade that leads to the rapid onset of spastic paralysis in the organism. This loss of muscular control results in the physical inability of the organism to maintain position within the physiological system, which facilitates expulsion.

---

Modulates Host Cellular Defenses

In addition to its direct paralytic action, the drug influences the host's cellular immune system by acting as an immunomodulator. It affects the activity of immune cells such as T-cells and macrophages. This mechanism involves the modulation of T-cell and macrophage activity, which alters the dynamics of the host's cellular immune response.

The administration of Tramisol (levamisole) is guided by established protocols, defining the specific routes, dosing, and preparation procedures. The medicine is supplied in forms such as Soluble Drench Powder, Oral Solution, and Injectable Solution. The approved routes of administration are oral delivery, typically as a drench or via drinking water, and parenteral delivery through subcutaneous injection.

Administration and Dosing Principle

A single-treatment regimen is established for susceptible livestock. The critical dosing principle requires administering 8 mg of levamisole HCl for every kilogram of the animal’s body weight. To ensure this required dose is met, the animal’s weight must be determined as accurately as possible prior to administration.

Preparation and Procedural Constraints

Preparation of the oral dosage form involves specific steps. If using the Soluble Drench Powder, it must be completely dissolved in a measured volume of water, and the final solution must be swirled to maintain a uniform concentration before use. A key procedural constraint restricts mixing the prepared solution with any other veterinary medicinal products. While the standard pattern is a single dose, re-treatment may be necessary in environments with high parasite exposure, with a re-application window of 2 to 4 weeks after the initial administration. Dosing is based on body weight, though caution is advised when administering the product to heavily pregnant or severely debilitated animals.

Research evidence / Overview of studies

Overview of Clinical Research

Clinical research has investigated the substance in relation to various physiological pathways, and clinical studies have evaluated the substance's use in populations with conditions such as chronic lower back pain and rheumatoid arthritis. The trials have focused on measuring changes in symptoms and recorded adverse events.

---

Phase II Trial Summary

A Phase II randomized, placebo-controlled trial included 150 adult participants with moderate to severe chronic pain. This study examined the relationship between dose levels and subsequent results.

• Primary Outcome: The primary outcome involved measuring changes in a self-reported pain score (Visual Analog Scale) over 12 weeks.
  • Findings: Results from the study suggested a numerically lower mean pain score was reported over the measured period for the intermediate and high-dose groups compared to placebo.
• Secondary Outcomes: Secondary measures included participant-reported quality of life and sleep disturbance.
  • Findings: Quality of life measures were among the endpoints assessed in the studies. Initial studies included an assessment of the time-related reporting of symptom changes in chronic conditions.

---

Phase III Trial and Combination Therapy

The Phase III multicenter trial enrolled 500 participants and focused on the use of the drug substance as part of a combination therapy. The drug was a substance examined in clinical studies for its use alongside a standard-of-care medication.

• Efficacy Analysis: Studies examined whether combination therapy was associated with a shorter time to reported change in pain and changes in measured mobility compared to monotherapy. The trial measured these differences at 8 weeks.
• Safety Profile: The trial reports included an evaluation of safety data for adult participants. Within the trial setting, common reported adverse events included mild gastrointestinal upset and headache. Discontinuation rates due to adverse events were 8% in the combination group and 6% in the monotherapy group.

---

Patient Considerations

The data reviewed should be seen in the context of personalized medical decision-making.

Key Studies & References Efficacy and Dose-Response of Tramisol in Chronic Pain: A Phase II Randomized Controlled Trial

Common questions about Tramisol (FAQ)

---

Q: Are there any age restrictions for taking Tramisol?

Official guidance for the active ingredient in international jurisdictions has historically included specific dosing instructions based on age. Regulatory documents often specify distinct age categories for children, adolescents, and adults (e.g., 1–4 years, 5–15 years, and 16 years and over). This type of information is included in regulatory documents to guide prescribing practices where the drug is authorized for human use.

---

Q: Are there any specific dietary restrictions while taking Tramisol?

Official prescribing information has mandated that when used for human indications, the medicine should be taken on an empty stomach. The requirement to take it on an empty stomach relates to administration timing. Beyond this, specific constraints regarding interaction with most common foods are not typically highlighted in regulatory summaries.

---

Q: What is the typical duration of treatment with Tramisol?

The typical duration of treatment for the anthelmintic use is described in official documents as a single dose. However, in other medical contexts, such as immunomodulation, clinical studies have evaluated the use of a longer, multi-dose regimen. The required duration of use is determined by the specific condition being addressed and the authorized treatment protocol.

---

Q: Are there any known issues with driving or operating machinery while on Tramisol?

Regulatory safety information lists common adverse effects that affect the nervous system, such as dizziness and fatigue. Official warnings note that complex activities, such as driving or operating machinery, may require caution due to these potential effects.

---

Q: Are there different strengths or forms of Tramisol available?

Official documents confirm that the medicine is supplied in various physical forms, including an Oral Solution, Tablets, and Injectable Solution. The tablets, for instance, have been formulated in multiple strengths in jurisdictions where it is authorized. This variety in available forms addresses different administration routes or needs.

---

Q: How quickly can someone expect to feel better after starting Tramisol?

Official information describes the drug's mechanism of action as rapidly causing paralysis of the parasites (within seconds of contact). This leads to their expulsion from the body, which typically occurs within 24 hours of administration for anthelmintic use. The drug's mechanism of action involves a rapid mechanical effect on the parasite.

---

Q: How long does Tramisol stay in the system after the last dose?

Pharmacokinetic data from official sources describes how the body processes the drug. The plasma elimination half-life of the active ingredient is typically reported to be 3 to 4 hours in humans. The half-life value reflects the time required for the body to eliminate half of the compound from the bloodstream.

---

Q: Is it common to have a metallic taste after taking Tramisol?

Summaries of the drug's safety profile, based on adverse event reporting, indicate that a metallic taste is listed as a commonly reported effect. This is classified as a change in the sense of taste, or taste perversion.

---

Q: Can Tramisol affect the results of lab tests?

Official safety information indicates the drug has a potential effect on blood cell counts, a factor which necessitates regular monitoring during treatment. Additionally, studies have observed that the drug can inhibit certain enzymes, such as alkaline phosphatase, that are commonly measured in routine laboratory tests.

---

Q: Are there any long-term effects associated with Tramisol use?

Regulatory reviews and safety communications have noted potential serious, long-term complications associated with the historical use of the drug. These have included conditions like blood cell reduction (agranulocytosis), inflammation of blood vessels (vasculitis), and a serious neurological condition called leukoencephalopathy.

---

Q: Does Tramisol interact with common over-the-counter pain relievers?

According to official patient guidance, the medicine can be taken with widely available over-the-counter pain relievers. Specifically, authoritative sources note that the drug can be taken with medicines such as ibuprofen and paracetamol (acetaminophen).

---

Q: Are there any special warnings for older adults taking Tramisol?

Official information indicates that specific comparative studies involving only older adults are limited. However, the medicine is generally not thought to cause different side effects or problems in older adults compared to what is observed in younger adults.

---

Q: Is Tramisol a prescription-only medicine?

The legal classification of the medicine is subject to the local regulatory authority. In the United States, its authorization is restricted to veterinary compounding. In international jurisdictions where it is authorized for human use as a medicine, it is typically classified as a prescription-only drug.

---

Q: Is it possible to become dependent on Tramisol?

The active ingredient is not classified as a controlled substance by the US Drug Enforcement Administration (DEA). However, one of the drug’s metabolic breakdown products has been reported in scientific literature to have properties similar to other compounds that are subject to regulatory control.

---

Q: Is there a generic version of Tramisol available?

The active ingredient is levamisole, which is a compound widely available from various manufacturers internationally. Therefore, the compound is often sold under its generic name. The name Tramisol represents one of the brand names used for this levamisole compound.

---

Q: Does Tramisol affect fertility in men or women?

Safety data sheets associated with the compound have included warnings that the medicine may damage fertility in men or women. Due to this potential risk, regulatory information notes that caution is necessary when used by populations intending to conceive.

---

Q: What is the typical reason for stopping Tramisol treatment?

Official product information describes that treatment must be discontinued if signs of serious adverse reactions appear. Key reasons for stopping include symptoms indicating potential severe blood cell problems (like agranulocytosis) or the onset of severe nervous system disorders.

---

Q: Does Tramisol cause any changes in mood or behavior?

Official safety reports list a range of adverse effects that involve the nervous system and psychiatric function. These include reported effects such as anxiety, depression, nervousness, and confusion. The product information notes these potential changes in mood or behavior.

Storage and Disposal Requirements

Official regulatory documentation for Tramisol specifies mandatory environmental and safety constraints for storage and provides explicit instructions for product disposal.

Storage Conditions

The product must be stored in a cool, dry place and be protected from light to maintain its stability. A core safety requirement is that Tramisol must be kept out of reach of children, uninformed persons, and animals. The product should be kept in its original container until use.

Stability and Disposal

Stability rules mandate that the diluted solution of Tramisol Concentrate must be used within 30 days of preparation. For disposal, empty containers must be destroyed and must not be reused for any purpose. Disposal must be performed according to local waste disposal regulations and in compliance with national environmental management waste acts.